<DOC>
	<DOCNO>NCT01588860</DOCNO>
	<brief_summary>Cholangiocarcinoma fatal malignant neoplasm originate biliary tract constitute 5-10 % primary liver cancer , characterize poor prognosis . High prevalence southeast eastern Asia observe . At present , cellular molecular mechanism lead oncogenesis cholangiocarcinoma remain unclear . The RAS gene product key role control cell growth differentiation intrinsic GTPase activity . Point mutation activate RAS protein downstream cascade observe human tumor . Both KRAS BRAF member RAS-RAF-MEK-ERK-MAP kinase pathway mediate cellular response growth signal . Somatic KRAS mutation find high rate leukemia , colon cancer , pancreatic cancer lung cancer . Studies European Japanese group recently describe activate KRAS/ BRAF mutation may play role carcinogenesis cholangiocarcinoma biliary tract , preliminary data demonstrate low frequency KRAS BRAF mutation tumor well result Thailand . In study , investigator hypothesize copy number change rather genetic mutation either KRAS BRAF gene may key finding Taiwanese case adenocarcinoma biliary tract .</brief_summary>
	<brief_title>Mutation Analysis Copy Number Changes KRAS BRAF Gene Taiwanese Cases Biliary Tact Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>The patient diagnose biliary tact adenocarcinoma .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>